-
Mashup Score: 5Nivolumab/Ipilimumab Maintains Prolonged Survival and Generates Durable Responses in Advanced RCC - 7 day(s) ago
First-line nivolumab/ipilimumab demonstrated sustained survival signals and responses vs sunitinib in previously untreated advanced RCC.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4VJHemOnc – The video journal of hematological oncology - 7 day(s) ago
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve the awareness and understanding of hematological cancers
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet-
#SOHO2023 is taking place next week in Houston, TX!📍 We @VJHemOnc are looking forward to interviewing and sharing the latest in #Leukemia, #Lymphoma and more. Follow us and check out https://t.co/O9p0vDBrzw to stay updated! @SocietyofHemOnc #LeuSM #LymSM #MMsm #MDSsm #MPNsm https://t.co/cQo18FkF3a
-
-
Mashup Score: 2SurgOnc Today® - Society of Surgical Oncology - 8 day(s) ago
SurgOnc Today® is an educational podcast for cancer surgeons from the Society of Surgical Oncology. Each episode features conversations with individuals who are experts within their respective fields and are members of SSO. Listen to the most recent episodes below or find all of the SurgOnc Today® episodes, organized by disease site, on ExpertEd@SSO and in the […]
Source: surgonc.orgCategories: General Medicine News, Onc News and JournalsTweet-
To close out AANHPI month, in this SurgOnc Today episode, we speak with some of the AANHPI leaders in surgical oncology around the US, providing insight into how their upbringing/heritage affected their careers in medicine. 🎙️https://t.co/nbKc4z56Jb https://t.co/74lHP3kGuX
-
-
Mashup Score: 4
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Onc News and JournalsTweet-
The #FDA granted accelerated approval to the combination of avutometinib + defactinib for patients with KRAS-mutated recurrent, low-grade serous #OvarianCancer. https://t.co/3Pef0Z2WbP https://t.co/6j6LuKtwvQ
-
-
Mashup Score: 2
Pirtobrutinib shows significant improvements in patient-reported outcomes for relapsed CLL/SLL, outperforming standard therapies in a recent trial.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
A recent analysis of the phase 3 BRUIN CLL-321 trial reveals that pirtobrutinib improved PROs vs standard regimens in R/R #CLL/SLL who had previously received a covalent BTK inhibitor. #EHA25 https://t.co/KbDDroUoAB
-
-
Mashup Score: 4ASH Foundation - 8 day(s) ago
The ASH Foundation is dedicated to moving hematology forward through charitable support for ASH programs – helping hematologists conquer blood diseases worldwide.
Source: www.hematology.orgCategories: General Medicine News, Onc News and JournalsTweet-
Help build a healthier future for those living with sickle cell disease. Support CONSA by donating to the ASH Foundation: 🔗 https://t.co/jT1fkS3bPT #SickleCell #Hematology https://t.co/vi09Hr1663
-
-
Mashup Score: 4VJHemOnc – The video journal of hematological oncology - 8 day(s) ago
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve the awareness and understanding of hematological cancers
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet-
#SOHO2023 is taking place next week in Houston, TX!📍 We @VJHemOnc are looking forward to interviewing and sharing the latest in #Leukemia, #Lymphoma and more. Follow us and check out https://t.co/O9p0vDBrzw to stay updated! @SocietyofHemOnc #LeuSM #LymSM #MMsm #MDSsm #MPNsm https://t.co/cQo18FkF3a
-
-
Mashup Score: 0
LYL314 elicited a complete response rate of 72%, with 71% lasting for 6 or more months in patients with large B-cell lymphoma in the third or later lines of therapy.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet-
In the third or later lines of treatment for those with R/R LBCL, LYL314 led to an ORR of 88% and a CR rate of 72%, with 71% of those patients remaining in a CR for 6 or more months. #lymsm https://t.co/osORQZHnW9
-
-
Mashup Score: 38
PURPOSEAdjuvant osimertinib is the standard of care for patients with resected epidermal growth factor receptor (EGFR)–mutated non–small cell lung cancer (NSCLC). Neoadjuvant treatment could improve surgical and long-term outcomes.METHODSIn this …
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet-
Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non–Small Cell Lung Cancer. Read full article. https://t.co/7WGW5FItmi
-
-
Mashup Score: 2
During a Community Case Forum event, Adil Daud, MD, discussed immunotherapy options for cutaneous squamous cell carcinoma.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
Adil Daud, MD, Evaluates Checkpoint Inhibitors in Advanced and Earlier Stages of #cSCC | @ad1600 @UCSFHospitals @UCSFCancer https://t.co/CNNAzn2HIv https://t.co/gXshGtTQqv
-
Nivolumab/Ipilimumab Maintains Prolonged Survival and Generates Durable Responses in Advanced RCC #RCC #kcsm #ASCO25 @ASCO https://t.co/splOFvySGT